window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 1, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Research & Development

  • Artificial Intelligence,Biotech,Movers & Shakers,Research & Development,Technology and platforms

    Sapio Sciences appoints Rich Roda as chief financial officer

    Sapio Sciences has appointed Rich Roda as chief financial officer, [...]

    October 6, 2025
  • Biotech,Oncology,Partnerships & Funding,Research & Development

    Myricx Bio appoints Boston-based Mohit Rawat as CEO and expands team in US and UK

    Myricx Bio has appointed Boston-based Mohit Rawat as chief executive [...]

    October 6, 2025
  • Cell & Gene Therapy,Clinical Trials,Drug approval,Rare Diseases,Research & Development

    AAVantgarde secures FDA orphan drug designation and UK trial approval for Stargardt gene therapy

    AAVantgarde Bio has received two regulatory milestones for its investigational [...]

    October 2, 2025
  • Cell & Gene Therapy,Clinical Development,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development

    CTMC and Einstein Hospital Israelita launch global cell therapy alliance

    CTMC, a joint venture between Resilience and MD Anderson Cancer [...]

    October 2, 2025
  • CDMOs & Manufacturing,Clinical Development,Oncology,Partnerships & Funding,Research & Development

    XenoSTART and Minerva Imaging expand collaboration on radiopharmaceutical drug development

    XenoSTART and Minerva Imaging have expanded their long-standing partnership to [...]

    October 2, 2025
  • Cell & Gene Therapy,Clinical studies,Clinical Trials,Pharmaceuticals and therapeutics,Research & Development

    EG 427 reports strong initial results for DNA therapy in neurogenic bladder trial

    EG 427 has released encouraging first clinical data from its [...]

    October 2, 2025
  • Biologics & Biosimilars,Clinical Development,Clinical Trials,Drug Development,Medical devices,Pharmaceuticals and therapeutics,Research & Development

    Xeltis reports positive EU key trial results for aXess, showing superior patency and safety in hemodialysis

    Xeltis’ aXess EU key trial shows sustained patency, fewer interventions, [...]

    October 2, 2025
  • Biologics & Biosimilars,Central Nervous System,Chronic diseases,Clinical Development,Clinical Trials,Drug Development,Pharmaceuticals and therapeutics,Research & Development

    Levicept to present Phase 2 LEVI-04 data showing bone marrow lesion and pain reduction at ACR Convergence 2025

    Levicept Ltd will present new findings from its Phase 2 [...]

    October 2, 2025
  • Biologics & Biosimilars,Clinical Development,Genetic Diseases,Rare Diseases,Research & Development,RNA Therapeutics

    Tevard Biosciences shows full-length protein rescue in Duchenne muscular dystrophy and dilated cardiomyopathy models

    Tevard Biosciences has presented new preclinical data demonstrating the potential [...]

    October 2, 2025
  • Biotech,Clinical Development,Clinical Trials,Drug Development,Global health,Partnerships & Funding,Rare Diseases,Research & Development

    SeaBeLife secures €2 million to advance dual-targeted therapies for dry AMD and severe acute hepatitis

    SeaBeLife, a biotechnology company developing novel drug candidates to block [...]

    October 1, 2025
Previous161718Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ImmuneOncia Therapeutics and Lonza agree manufacturing partnership for PD-L1 antibody Danburstotug
    Categories: CDMOs & Manufacturing, Cell & Gene Therapy, Immunology, Oncology, Pharmaceuticals and therapeutics, Rare Diseases, Research & Development
  • Vetter recognised as 2026 CDMO Leadership Awards winner in finished dose category
    Categories: CDMOs & Manufacturing, Manufacturing, Market Access & Commercialization, Pharmaceuticals and therapeutics
  • UMass Chan, Caring Cross and Trenchant BioSystems form sickle cell gene therapy manufacturing alliance
    Categories: Cell & Gene Therapy, Hematology, Manufacturing, Partnerships & Funding, Rare Diseases, Research & Development, Technology and platforms
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top